Global Hepatitis E Market, By Drug Class (Antiviral Drugs, Interferons, Others), Route of Administration (Oral, Parenteral, Others), End-Users (Hospitals, Homecare, Specialty Clinics, Others), Distribution Channel (Hospital Pharmacy, Online Pharmacy, Retail Pharmacy) – Industry Trends and Forecast to 2029.
Hepatitis E Market Analysis and Size
The hepatitis E market is expected to witness significant growth during the forecast period. Emerging markets and huge investment in research and development are the factors responsible for the growth of this market. The growth of hepatitis E market enhanced by the growing cases of hepatitis E and rise in the research and development activities conducted by many pharmaceuticals’ companies. In addition, advances in the treatment options and the presence of well-established healthcare facilities are some of the impacting factors for the demand of Hepatitis E market. COVID-19 also had a major impact on the market growth.
Data Bridge Market Research analyses a growth rate in the global hepatitis E market in the forecast period 2022-2029. The hepatitis E market is tend to have a healthy CAGR in the mentioned forecast period. In addition to the market insights such as market value, growth rate, market segments, geographical coverage, market players, and market scenario, the market report curated by the Data Bridge Market Research team also includes in-depth expert analysis, patient epidemiology, pipeline analysis, pricing analysis, and regulatory framework.
Hepatitis E Market Scope and Segmentation
|
Report Metric
|
Details
|
|
Forecast Period
|
2022 to 2029
|
|
Base Year
|
2021
|
|
Historic Years
|
2020 (Customizable to 2014 - 2019)
|
|
Quantitative Units
|
Revenue in USD Million, Volumes in Units, Pricing in USD
|
|
Segments Covered
|
Drug Class (Antiviral Drugs, Interferons, Others), Route of Administration (Oral, Parenteral, Others), End-Users (Hospitals, Homecare, Specialty Clinics, Others), Distribution Channel (Hospital Pharmacy, Online Pharmacy, Retail Pharmacy)
|
|
Countries Covered
|
U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America
|
|
Market Players Covered
|
Pfizer Inc. (U.S.), GSK plc (U.K.), Novartis AG (Switzerland), Mylan N.V. (U.S.), Teva Pharmaceutical Industries Ltd. (Israel), Sanofi (France), Boehringer Ingelheim International GmbH. (Germany), AstraZeneca (U.K.), Johnson & Johnson Private Limited (U.S.), Bayer AG (Germany), Merck & Co., Inc. (U.S.), F. Hoffmann-La Roche Ltd. (Switzerland), Bristol-Myers Squibb Company (U.S.), Cadila Pharmaceuticals (India)
|
|
Market Opportunities
|
|
Market Definition
Hepatitis E, also known as hepatitis E virus (HEV), is a viral liver inflammation disease. This virus is spread primarily by faecal-oral transmission and contaminated food and water. Although hepatitis E virus often causes acute and self-limiting infection as virus usually does not take too long-term illness and resolves itself. However, immunocompromised patients can lead to life-threatening conditions or even death.
Global Hepatitis E Market Dynamics
Drivers
- Prevalence of Hepatitis E
According to World Health Organizations in July 2020, each year there is an estimated 20 million Hepatitis E infections worldwide which leads to a 3.3 million symptomatic cases of hepatitis E. Thus, it boosts the market growth.
- Rising Demand for Oral Drugs
Oral drugs is expected to boost the market growth. The segment is expected to accelerate the global market as most products are available in capsule and tablet form and it is a very feasible route of administration.
Opportunities
- Increasing Demand for Retail Pharmacies
Rise in the number of hepatitis E therapeutics being delivered through retail pharmacies and surge in the number of retail pharmacies in developed countries create opportunities for the market growth. In addition to this, patients prefer retail pharmacies for purchasing drugs, as these are easily accessible.
- Increase in Geriatric Population
The geriatric population is expected to increase the patient population globally, which boots the global hepatitis E market in the forecast period. According to the WHO, the global elderly population is expected to reach around 2 billion by 2050 from 617 million in 2015. This boost the market growth.
Restraints/Challenges
- Lack of skilled professionals
The lack of qualified personnel who are unable to treat the patients with appropriate treatments could curb the growth of the global hepatitis E market over a forecast period.
- High Cost
The huge expenditure associated with Hepatitis E treatment medications surely hamper the market growth.
This global hepatitis E market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the global hepatitis E market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.
COVID-19 Impact on Global Hepatitis E Market
Considering the present scenario, COVID-19 has left an unprecedented global public health crisis that has impacted practically every business, and its long-term repercussions are expected to have an influence on industry growth during the forecast period. Transition of healthcare infrastructure toward managing COVID-19 has led to drug launch cancellations and delays in clinical trials. The unavailability of the specific COVID-19 tests presented positive opportunities for the manufacturers to introduce their COVID-19 diagnostic kits. Many major market players as well as many start-ups from several countries are gathering up to boost the market growth.
Global Hepatitis E Market Scope
The global hepatitis E market is segmented on the basis of drug class, distribution channel and end-user. The growth amongst these segments will help you analyze meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.
Drug Class
- Antiviral Drugs
- Interferons
- Others
End User
- Hospitals
- Homecare
- Specialty Clinics
- Others
Distribution Channel
- Hospital Pharmacy
- Online Pharmacy
- Retail Pharmacy
Global Hepatitis E Market Regional Analysis/Insights
The global hepatitis E market is analysed and market size insights and trends are provided by drug class, distribution channel and end-user as referenced above.
The major countries covered in the global hepatitis E market report are the U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America.
North America has been witnessing a positive growth for global hepatitis E market throughout the forecasted period due to the high prevalence of hepatitis E, high diagnostic rate and presence of sophisticated medical facilities in order to optimize the treatment for patient suffering from the hepatitis E.
Asia-Pacific dominates the market due to the developing healthcare facilities, large number of generic manufacturer and rise in government initiatives and specialist communities.
The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Also, the presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data.
Competitive Landscape and Global Hepatitis E Market Share Analysis
The global hepatitis E market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies' focus related to global hepatitis E market.
Key players operating in the global hepatitis E market include:
- Pfizer Inc. (U.S.)
- GSK plc (U.K.)
- Novartis AG (Switzerland)
- Mylan N.V. (U.S.)
- Teva Pharmaceutical Industries Ltd.(Israel)
- Sanofi (France)
- Boehringer Ingelheim International GmbH. (Germany)
- AstraZeneca (U.K.)
- Johnson & Johnson Private Limited (U.S.)
- Bayer AG (Germany)
- Merck & Co., Inc. (U.S.)
- F. Hoffmann-La Roche Ltd. (Switzerland)
- Bristol-Myers Squibb Company (U.S.)
- Cadila Pharmaceuticals (India)
SKU-